Clinical Trial Update: SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SMAC mimetic LCL161 alone or with cyclophosphamide in relapsed or refractory multiple myeloma; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LCL161

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-02-07